3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluorooctan-1-ol
Associated AOPs with Level of Relevance - 1 AOPs with at least 1 KE associated with chemical, where the KE(s) are neither MIE nor AO
| AOP Identifier |
AOP Title |
AO Classification |
OECD Status |
Taxonomic applicability |
Coverage Score
ⓘ
The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints.
|
KE Identifier |
KE Name |
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.12 | KE:288 | Activation of specific nuclear receptors, Transcriptional change |
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.14 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:232 | NFE2/Nrf2 repression to steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | | 0.12 | KE:1419 | Reduced, FXR activity |
| AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign neoplasm; Endocrine system disease; Reproductive system disease; Reproductive system disease; Cancer; Endocrine system disease | Under Development | Human, Rat, Mice | 0.11 | KE:1973 | Increased, estrogens |
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity |
| AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular system disease | - | Human, Mouse, Rat | 0.2 | KE:2066 | Altered Signaling Pathways |
Associated AOPs with Level of Relevance - 2 AOPs with at least 1 AO associated with chemical, and no associated MIE
| AOP Identifier |
AOP Title |
AO Classification |
OECD Status |
Taxonomic applicability |
Coverage Score
ⓘ
The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints.
|
KE Identifier |
KE Name |
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
Associated AOPs with Level of Relevance - 3 AOPs with at least 1 MIE associated with chemical, and no associated AO
| AOP Identifier |
AOP Title |
AO Classification |
OECD Status |
Taxonomic applicability |
Coverage Score
ⓘ
The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints.
|
KE Identifier |
KE Name |
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | | 0.17 | KE:10008 | Increased transcription for detoxification and repair mechanism |
| AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | | 0.12 | KE:10008 | Increased transcription for detoxification and repair mechanism |
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | | 0.12 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | | 0.2 | KE:111 | Agonism, Estrogen receptor |
No associated AOPs with Level of Relevance 5
DISCLAIMER
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.